• Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

  • 2024/07/15
  • 再生時間： 9 分
  • ポッドキャスト

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices
身体的病い・疾患 衛生・健康的な生活 生物科学
続きを読む 一部表示

Strategies to Limit ARIA Associated with Alzheimer Disease Treatmentに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。